<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03547167</url>
  </required_header>
  <id_info>
    <org_study_id>V114-017</org_study_id>
    <secondary_id>2017-004915-38</secondary_id>
    <secondary_id>V114-017</secondary_id>
    <nct_id>NCT03547167</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to 1) describe the safety, tolerability, and immunogenicity of V114&#xD;
      and Prevnar 13™ in pneumococcal vaccine-naïve adults at increased risk for pneumococcal&#xD;
      disease and to 2) describe the safety, tolerability, and immunogenicity of PNEUMOVAX™23 when&#xD;
      administered 6 months after receipt of either V114 or Prevnar 13™. Increased risk for&#xD;
      pneumococcal disease is defined as 1) an underlying medical condition, 2) behavioral habits&#xD;
      such as smoking or alcohol use, or 3) living in a community/environment with increased risk&#xD;
      of disease transmission.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 16, 2018</start_date>
  <completion_date type="Actual">January 20, 2020</completion_date>
  <primary_completion_date type="Actual">January 20, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Solicited Injection-site Adverse Events Following V114 or Prevnar 13™</measure>
    <time_frame>Up to 5 days after Vaccination 1</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Following Vaccination 1 with either V114 or Prevnar 13™, the percentage of participants with solicited injection-site AEs was assessed. The solicited injection-site AEs assessed were redness/erythema, swelling, and tenderness/pain. Estimated confidence intervals (CIs) are calculated based on the exact binomial method proposed by Clopper and Pearson.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Solicited Systemic Adverse Events Following V114 or Prevnar 13™</measure>
    <time_frame>Up to 14 days after Vaccination 1</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Following vaccination with V114 or Prevnar 13™, the percentage of participants with solicited systemic AEs was assessed. The solicited systemic AEs assessed were muscle pain/myalgia, joint pain/arthralgia, headache, and tiredness/fatigue. Estimated CIs are calculated based on the exact binomial method proposed by Clopper and Pearson.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Vaccine-related Serious Adverse Event Following V114 or Prevnar 13™</measure>
    <time_frame>Up to Month 6 (before Vaccination 2)</time_frame>
    <description>A serious adverse event (SAE) is an AE that is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Relatedness of an SAE to the study vaccine was determined by the investigator. Following vaccination with V114 or Prevnar 13™, the percentage of serious adverse events of V114 compared with Prevnar 13™ was assessed. Estimated CIs are calculated based on the exact binomial method proposed by Clopper and Pearson.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titer of Serotype-specific Opsonophagocytic Activity Day 30 Following V114 or Prevnar 13™</measure>
    <time_frame>Day 30</time_frame>
    <description>The geometric mean titer (GMT) of serotype-specific opsonophagocytic activity (OPA) for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using a multiplex opsonophagocytic assay. The within-group 95% CIs are obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Solicited Injection-site Adverse Events Following PNEUMOVAX™23</measure>
    <time_frame>Up to 5 days after Vaccination 2 (Month 6)</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Following Vaccination 2 with PNEUMOVAX™23, the percentage of participants with solicited injection-site AEs was assessed. The solicited injection-site AEs assessed were redness/erythema, swelling, and tenderness/pain. Estimated CIs are calculated based on the exact binomial method proposed by Clopper and Pearson and are provided in accordance with the statistical analysis plan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Solicited Systemic Adverse Events Following PNEUMOVAX™23</measure>
    <time_frame>Up to 14 days after Vaccination 2 (Month 6)</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Following Vaccination 2 with PNEUMOVAX™23, the percentage of participants with solicited systemic AEs was assessed. The solicited systemic AEs assessed were muscle pain/myalgia, joint pain/arthralgia, headache, and tiredness/fatigue. Estimated CIs are calculated based on the exact binomial method proposed by Clopper and Pearson.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Vaccine-related Serious Adverse Event Following PNEUMOVAX™23</measure>
    <time_frame>From Month 6 (before Vaccination 2) to Month 7</time_frame>
    <description>A serious adverse event (SAE) is an AE that is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Relatedness of an SAE to the study vaccine was determined by the investigator. Following vaccination with PNEUMOVAX™23, the percentage of serious adverse events of V114 compared with Prevnar 13™ was assessed. Estimated CIs are calculated based on the exact binomial method proposed by Clopper and Pearson.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration of Serotype-specific Immunoglobulin G at Day 30</measure>
    <time_frame>Day 30</time_frame>
    <description>The geometric mean concentration (GMC) of serotype-specific immunoglobulin G (IgG) for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using an electrochemiluminescence assay. The within-group 95% CIs are obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise in Serotype-specific OPA Day 1 to Day 30</measure>
    <time_frame>Day 1 (Baseline) and Day 30</time_frame>
    <description>Activity for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using a Multiplex Opsonophagocytic Assay. Geometric mean fold rise (GMFR) is the geometric mean of fold rise from baseline to postvaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFR in Serotype-specific IgG Day 1 to Day 30</measure>
    <time_frame>Day 1 (Baseline) and Day 30</time_frame>
    <description>IgG for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using an electrochemiluminescence assay. GMFR is the geometric mean of fold rise from baseline to postvaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ≥4-Fold Rise in Serotype-specific OPA Day 1 to Day 30</measure>
    <time_frame>Day 1 (Baseline) and Day 30</time_frame>
    <description>Activity for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using a Multiplexed Opsonophagocytic Assay. The percentage of participants who had ≥4-fold rise in OPA titers were calculated from baseline to postvaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ≥4-Fold Rise in Serotype-specific IgG Day 1 to Day 30</measure>
    <time_frame>Day 1 (Baseline) and Day 30</time_frame>
    <description>IgG for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using an electrochemiluminescence assay. The percentage of participants who had ≥ 4-fold rise in IgG concentration are calculated from baseline to postvaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer of Serotype-specific OPA at Month 7</measure>
    <time_frame>Month 7</time_frame>
    <description>The geometric mean titer (GMT) of serotype-specific OPA for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using a multiplex opsonophagocytic assay. The within-group 95% CIs are obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration of Serotype-specific IgG at Month 7</measure>
    <time_frame>Month 7</time_frame>
    <description>The geometric mean concentration (GMC) of serotype-specific immunoglobulin G (IgG) for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using an electrochemiluminescence assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFR in Serotype-specific OPA Day 1 to Month 7</measure>
    <time_frame>Day 1 (Baseline) and Month 7</time_frame>
    <description>Activity for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using a Multiplexed Opsonophagocytic Assay. Geometric mean fold rise (GMFR) is the geometric mean of fold rise from baseline to postvaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFR in Serotype-specific IgG Day 1 to Month 7</measure>
    <time_frame>Day 1 (Baseline) and Month 7</time_frame>
    <description>IgG for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using an electrochemiluminescence assay. GMFR is the geometric mean of fold rise from baseline to postvaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ≥4-Fold Rise in Serotype-specific OPA Day 1 to Month 7</measure>
    <time_frame>Day 1 (Baseline) and Month 7</time_frame>
    <description>Activity for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using a Multiplexed Opsonophagocytic Assay. The percentage of participants who had ≥4-fold rise in OPA titers were calculated from baseline to postvaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ≥4-Fold Rise in Serotype-specific IgG Day 1 to Month 7</measure>
    <time_frame>Day 1 (Baseline) and Month 7</time_frame>
    <description>IgG for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using an electrochemiluminescence assay. The percentage of participants who had ≥ 4-fold rise in IgG concentration are calculated from baseline to postvaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFR in Serotype-specific OPA Month 6 to Month 7</measure>
    <time_frame>Month 6 (Baseline before Vaccination 2) and Month 7</time_frame>
    <description>Activity for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using the Multiplexed Opsonophagocytic Assay. Geometric mean fold rise (GMFR) is the geometric mean of fold rise from baseline to postvaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFR in Serotype-specific IgG Month 6 to Month 7</measure>
    <time_frame>Month 6 (Baseline before Vaccination 2) and Month 7</time_frame>
    <description>IgG for the serotypes contained in Prevnar 13™ and V114 and (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using an electrochemiluminescence assay. GMFR is the geometric mean of fold rise from baseline to postvaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ≥4-Fold Rise in Serotype-specific OPA Month 6 to Month 7</measure>
    <time_frame>Month 6 (Baseline before Vaccination 2) and Month 7</time_frame>
    <description>Activity for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using a Multiplexed Opsonophagocytic Assay. The percentage of participants who had ≥4-fold rise in OPA titers were calculated from baseline to postvaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ≥4-Fold Rise in Serotype-specific IgG Month 6 to Month 7</measure>
    <time_frame>Month 6 (Baseline before Vaccination 2) and Month 7</time_frame>
    <description>IgG for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using an electrochemiluminescence assay. The percentage of participants who had ≥ 4-fold rise in IgG concentration are calculated from baseline to postvaccination.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1515</enrollment>
  <condition>Pneumococcal Infections</condition>
  <arm_group>
    <arm_group_label>V114</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prevnar 13™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V114</intervention_name>
    <description>15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose</description>
    <arm_group_label>V114</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevnar 13™</intervention_name>
    <description>13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg), and aluminum phosphate adjuvant (125 mcg aluminum) in each 0.5 ml dose</description>
    <arm_group_label>Prevnar 13™</arm_group_label>
    <other_name>PCV13</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PNEUMOVAX™23</intervention_name>
    <description>23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose</description>
    <arm_group_label>Prevnar 13™</arm_group_label>
    <arm_group_label>V114</arm_group_label>
    <other_name>PPV23</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Native American participant enrolled from any of the clinical sites of the Johns&#xD;
             Hopkins Center for American Indian Health (CAIH) without any of the pre-specified risk&#xD;
             conditions for pneumococcal disease listed below, OR Native American participant&#xD;
             enrolled from any of the CAIH sites or participant from a site other than CAIH with ≥1&#xD;
             of the following risk conditions for pneumococcal disease:&#xD;
&#xD;
               1. Diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) &lt;10%&#xD;
&#xD;
               2. Chronic liver disease with documented history of compensated cirrhosis&#xD;
                  (Child-Pugh Score A)&#xD;
&#xD;
               3. Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with&#xD;
                  spirometric Global Initiative for Chronic Obstructive Lung Disease Stage 1 to 3&#xD;
&#xD;
               4. Confirmed diagnosis of mild or moderate persistent asthma receiving guideline&#xD;
                  directed therapy&#xD;
&#xD;
               5. Confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA]&#xD;
                  heart failure Class 1 to 3, receiving guideline-directed oral heart failure&#xD;
                  treatment) due to reduced or preserved ejection fraction or due to non-cyanotic&#xD;
                  congenital heart disease.&#xD;
&#xD;
               6. Current smoker&#xD;
&#xD;
          -  Female participant: not pregnant, not breastfeeding and 1) not of childbearing&#xD;
             potential, or 2) of childbearing potential and agrees to practice contraception&#xD;
             through 6 weeks after last administration of study vaccine.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of active hepatitis within the prior 3 months&#xD;
&#xD;
          -  History of diabetic ketoacidosis, or &gt;1 episodes of severe, symptomatic hypoglycemia&#xD;
             within the prior 3 months&#xD;
&#xD;
          -  Myocardial infarction, acute coronary syndrome, transient ischemic attack, and&#xD;
             ischemic or hemorrhagic stroke within the prior 3 months&#xD;
&#xD;
          -  History of severe pulmonary hypertension or history of Eisenmenger syndrome&#xD;
&#xD;
          -  History of invasive pneumococcal disease (IPD) or known history of other&#xD;
             culture-positive pneumococcal disease within the prior 3 years&#xD;
&#xD;
          -  Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or&#xD;
             diphtheria toxoid-containing vaccine&#xD;
&#xD;
          -  Known or suspected impairment of immunological function (including human&#xD;
             immunodeficiency virus (HIV) infection or autoimmune disease)&#xD;
&#xD;
          -  History of malignancy within the prior 5 years, except for adequately treated basal&#xD;
             cell or squamous cell skin cancer or in situ cervical cancer&#xD;
&#xD;
          -  History of Stage 4 or 5 Chronic Kidney Disease or nephrotic syndrome&#xD;
&#xD;
          -  History of alcohol withdrawal or alcohol withdrawal seizure within the prior 12 months&#xD;
&#xD;
          -  History of coagulation disorder contraindicating intramuscular vaccination&#xD;
&#xD;
          -  History of hospitalization within the prior 3 months&#xD;
&#xD;
          -  Planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other&#xD;
             planned major surgery during the duration of this study.&#xD;
&#xD;
          -  Expected survival for less than 1 year according to the investigator's judgment.&#xD;
&#xD;
          -  Female participant: positive urine or serum pregnancy test&#xD;
&#xD;
          -  Prior administration of any pneumococcal vaccine&#xD;
&#xD;
          -  Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14&#xD;
             consecutive days and has not completed within the prior 30 days&#xD;
&#xD;
          -  Received systemic corticosteroids exceeding physiologic replacement doses within 14&#xD;
             days before study vaccination&#xD;
&#xD;
          -  Receiving immunosuppressive or immunomodulatory therapy with a biological agent&#xD;
&#xD;
          -  Received any licensed, non-live vaccine within 14 days before receipt of study vaccine&#xD;
             or is scheduled to receive any licensed, non-live vaccine within 30 days following&#xD;
             receipt of study vaccine&#xD;
&#xD;
          -  Received any live vaccine within 30 days before receipt of any study vaccine or is&#xD;
             scheduled to receive any live vaccine within 30 days following receipt of any study&#xD;
             vaccine&#xD;
&#xD;
          -  Received a blood transfusion or blood products within the prior 6 months&#xD;
&#xD;
          -  Receiving chronic home oxygen therapy&#xD;
&#xD;
          -  Participated in another clinical study of an investigational product within the prior&#xD;
             2 months&#xD;
&#xD;
          -  Current user of recreational or illicit drugs or history of drug abuse or dependence&#xD;
&#xD;
          -  Diabetes mellitus with HgA1c ≥10%&#xD;
&#xD;
          -  Chronic liver disease with Child-Pugh Class B or C cirrhosis&#xD;
&#xD;
          -  Chronic lung disease with Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or&#xD;
             severe persistent asthma&#xD;
&#xD;
          -  Chronic heart disease with NYHA heart failure Class 4.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chinle Comprehensive Health Care Facility ( Site 0001)</name>
      <address>
        <city>Chinle</city>
        <state>Arizona</state>
        <zip>86503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Defiance Center for American Indian Health ( Site 0002)</name>
      <address>
        <city>Fort Defiance</city>
        <state>Arizona</state>
        <zip>86504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary Associates, PA ( Site 0043)</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Phoenix Medical Clinic, LLC ( Site 0031)</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Whiteriver Center for American Indian Health ( Site 0005)</name>
      <address>
        <city>Whiteriver</city>
        <state>Arizona</state>
        <zip>85941</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inland Empire Clinical Trials, LLC ( Site 0052)</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92377</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Top Medical Research, Inc ( Site 0033)</name>
      <address>
        <city>Cutler Bay</city>
        <state>Florida</state>
        <zip>33189</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indago Research &amp; Health Center, Inc ( Site 0054)</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renstar Medical Research ( Site 0008)</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Triple O Research Institute, P.A. ( Site 0026)</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine at Grady Hospital ( Site 0027)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kootenai Health ( Site 0042)</name>
      <address>
        <city>Coeur d'Alene</city>
        <state>Idaho</state>
        <zip>83814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evanston Premier Healthcare &amp; Research, LLC. ( Site 0012)</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmakon Inc ( Site 0049)</name>
      <address>
        <city>Evergreen Park</city>
        <state>Illinois</state>
        <zip>60805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reid Physician Associates ( Site 0055)</name>
      <address>
        <city>Richmond</city>
        <state>Indiana</state>
        <zip>47374</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Pharmaceutical Research PC ( Site 0050)</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consortium ( Site 0053)</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal Medicine Associates [Bridgeton, NJ] ( Site 0015)</name>
      <address>
        <city>Bridgeton</city>
        <state>New Jersey</state>
        <zip>08302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gallup Center for American Indian Health ( Site 0003)</name>
      <address>
        <city>Gallup</city>
        <state>New Mexico</state>
        <zip>87301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shiprock Center for American Indian Health ( Site 0004)</name>
      <address>
        <city>Shiprock</city>
        <state>New Mexico</state>
        <zip>87420</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corning Center For Clinical Research ( Site 0036)</name>
      <address>
        <city>Corning</city>
        <state>New York</state>
        <zip>14830</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Hudson Medical Research ( Site 0022)</name>
      <address>
        <city>New Windsor</city>
        <state>New York</state>
        <zip>12553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates, LLC ( Site 0016)</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Health Network ( Site 0040)</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania ( Site 0030)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mountain View Clinical Research ( Site 0007)</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holston Medical Group ( Site 0025)</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIM Trials ( Site 0060)</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch at Galveston ( Site 0034)</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-1115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice Leadership, LLC ( Site 0051)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77094</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Center For Drug Development ( Site 0041)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Institute Of Cardiology ( Site 0048)</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <zip>75071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Village Health Partners ( Site 0006)</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Copperview Medical Center ( Site 0038)</name>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Timber Lane Allergy &amp; Asthma Research, LLC ( Site 0044)</name>
      <address>
        <city>South Burlington</city>
        <state>Vermont</state>
        <zip>05403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary &amp; Sleep Research ( Site 0046)</name>
      <address>
        <city>Spokane Valley</city>
        <state>Washington</state>
        <zip>99216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gundersen Health System ( Site 0021)</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic ( Site 0013)</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paratus Clinical Pty Ltd - Blacktown Clinic ( Site 0174)</name>
      <address>
        <city>Blacktown</city>
        <state>New South Wales</state>
        <zip>2148</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holdsworth House Medical Practice ( Site 0170)</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Core Research Group Pty limited ( Site 0175)</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4064</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emeritus Research Pty Ltd ( Site 0173)</name>
      <address>
        <city>Camberwell</city>
        <state>Victoria</state>
        <zip>3124</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paratus Clinical Kanwal ( Site 0172)</name>
      <address>
        <city>Kanwal</city>
        <zip>2259</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nepean Hospital ( Site 0176)</name>
      <address>
        <city>Kingswood</city>
        <zip>2747</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Liver and Intestinal Research Centre (LAIR) ( Site 0302)</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1H2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GA Research Associates, Ltd/Ltee ( Site 0303)</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1G 1A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colchester Research Group ( Site 0094)</name>
      <address>
        <city>Truro</city>
        <state>Nova Scotia</state>
        <zip>B2N 1L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Medical Research Group ( Site 0092)</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8M 1K7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SKDS Research Inc. ( Site 0099)</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omnispec Recherche Clinique Inc ( Site 0093)</name>
      <address>
        <city>Mirabel</city>
        <state>Quebec</state>
        <zip>J7J 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dynamik Research ( Site 0095)</name>
      <address>
        <city>Pointe-Claire</city>
        <state>Quebec</state>
        <zip>H9R 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Q &amp; T Research Sherbrooke Inc. ( Site 0097)</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1J 2G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diex Recherche Quebec Inc ( Site 0091)</name>
      <address>
        <city>Quebec</city>
        <zip>G1N 4V3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Arauco Salud ( Site 0100)</name>
      <address>
        <city>Santiago</city>
        <state>RM</state>
        <zip>7560994</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion Clinica UC CICUC ( Site 0104)</name>
      <address>
        <city>Santiago</city>
        <zip>8330034</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CECIM ( Site 0101)</name>
      <address>
        <city>Santiago</city>
        <zip>8330336</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CESFAM Esmeralda ( Site 0102)</name>
      <address>
        <city>Santiago</city>
        <zip>9351603</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Dr. Hernan Henriquez Aravena ( Site 0105)</name>
      <address>
        <city>Temuco</city>
        <zip>4781151</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Clinical Trials - Waitemata ( Site 0183)</name>
      <address>
        <city>Auckland</city>
        <zip>0626</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Clinical Studies Limited ( Site 0189)</name>
      <address>
        <city>Auckland</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimal Clinical Trials ( Site 0182)</name>
      <address>
        <city>Auckland</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Heart Institute ( Site 0280)</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Clinical Trials Ltd ( Site 0180)</name>
      <address>
        <city>Christchurch</city>
        <zip>8013</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeland Clinical Trials ( Site 0181)</name>
      <address>
        <city>Rotorua</city>
        <zip>3010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay of Plenty Clinical School ( Site 0186)</name>
      <address>
        <city>Tauranga</city>
        <zip>3143</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P3 Research Ltd - Wellington ( Site 0184)</name>
      <address>
        <city>Wellington</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WSOZ im.T.Browicza w Bydgoszczy ( Site 0317)</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-030</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Pratia Bydgoszcz ( Site 0139)</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-796</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Sp. z o.o. ( Site 0238)</name>
      <address>
        <city>Gdansk</city>
        <zip>80-382</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczny osrodek .All-Med. Grazyna Pulka ( Site 0233)</name>
      <address>
        <city>Krakow</city>
        <zip>30-033</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ID Clinic ( Site 0235)</name>
      <address>
        <city>Myslowice</city>
        <zip>41-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Ogrodowa Sp. Z o.o. ( Site 0319)</name>
      <address>
        <city>Skierniewice</city>
        <zip>96-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej ( Site 0314)</name>
      <address>
        <city>Sopot</city>
        <zip>81-717</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wroclawskie Centrum Zdrowia SP ZOZ ( Site 0236)</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-136</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Sp. z o.o. oddział we Wrocławiu ( Site 0234)</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-381</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Hospital of Infectious Diseases n. a. A.F.Agafonov ( Site 0249)</name>
      <address>
        <city>Kazan</city>
        <zip>420140</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saratov State Medical University n.a. V.I.Razumovskiy ( Site 0144)</name>
      <address>
        <city>Saratov</city>
        <zip>410054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smolensk State Medical University ( Site 0246)</name>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>May 24, 2018</study_first_submitted>
  <study_first_submitted_qc>May 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2018</study_first_posted>
  <results_first_submitted>December 14, 2020</results_first_submitted>
  <results_first_submitted_qc>December 21, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 15, 2021</results_first_posted>
  <last_update_submitted>December 21, 2020</last_update_submitted>
  <last_update_submitted_qc>December 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 31, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT03547167/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>V114</title>
          <description>Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
        </group>
        <group group_id="P2">
          <title>Prevnar 13™</title>
          <description>Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1135"/>
                <participants group_id="P2" count="380"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination 1 - (V114 or Prevnar 13™, Day 1)</title>
              <participants_list>
                <participants group_id="P1" count="1133"/>
                <participants group_id="P2" count="379"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination 2 - (PNEUMOVAX™23, Month 6)</title>
              <participants_list>
                <participants group_id="P1" count="1035"/>
                <participants group_id="P2" count="346"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1038"/>
                <participants group_id="P2" count="350"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants who received at least 1 dose of study vaccination.</population>
      <group_list>
        <group group_id="B1">
          <title>V114</title>
          <description>Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
        </group>
        <group group_id="B2">
          <title>Prevnar 13™</title>
          <description>Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1135"/>
            <count group_id="B2" value="380"/>
            <count group_id="B3" value="1515"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.9" spread="8.9"/>
                    <measurement group_id="B2" value="35.8" spread="8.9"/>
                    <measurement group_id="B3" value="35.8" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="581"/>
                    <measurement group_id="B2" value="201"/>
                    <measurement group_id="B3" value="782"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="554"/>
                    <measurement group_id="B2" value="179"/>
                    <measurement group_id="B3" value="733"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="174"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="984"/>
                    <measurement group_id="B2" value="338"/>
                    <measurement group_id="B3" value="1322"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="445"/>
                    <measurement group_id="B2" value="148"/>
                    <measurement group_id="B3" value="593"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="582"/>
                    <measurement group_id="B2" value="192"/>
                    <measurement group_id="B3" value="774"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Solicited Injection-site Adverse Events Following V114 or Prevnar 13™</title>
        <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Following Vaccination 1 with either V114 or Prevnar 13™, the percentage of participants with solicited injection-site AEs was assessed. The solicited injection-site AEs assessed were redness/erythema, swelling, and tenderness/pain. Estimated confidence intervals (CIs) are calculated based on the exact binomial method proposed by Clopper and Pearson.</description>
        <time_frame>Up to 5 days after Vaccination 1</time_frame>
        <population>The analysis population included all randomized participants who received the relevant study vaccination for the timepoint of interest and were included in the intervention group according to the intervention they received. One participant in the Prevnar 13™ group incorrectly received V114 and was included in the V114 group for safety analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>V114</title>
            <description>Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
          <group group_id="O2">
            <title>Prevnar 13™</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Solicited Injection-site Adverse Events Following V114 or Prevnar 13™</title>
          <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Following Vaccination 1 with either V114 or Prevnar 13™, the percentage of participants with solicited injection-site AEs was assessed. The solicited injection-site AEs assessed were redness/erythema, swelling, and tenderness/pain. Estimated confidence intervals (CIs) are calculated based on the exact binomial method proposed by Clopper and Pearson.</description>
          <population>The analysis population included all randomized participants who received the relevant study vaccination for the timepoint of interest and were included in the intervention group according to the intervention they received. One participant in the Prevnar 13™ group incorrectly received V114 and was included in the V114 group for safety analyses.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1134"/>
                <count group_id="O2" value="378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site redness/erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" lower_limit="13.0" upper_limit="17.3"/>
                    <measurement group_id="O2" value="14.0" lower_limit="10.7" upper_limit="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site tenderness/pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.8" lower_limit="73.2" upper_limit="78.3"/>
                    <measurement group_id="O2" value="68.8" lower_limit="63.8" upper_limit="73.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.7" lower_limit="19.3" upper_limit="24.2"/>
                    <measurement group_id="O2" value="22.2" lower_limit="18.1" upper_limit="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Solicited Systemic Adverse Events Following V114 or Prevnar 13™</title>
        <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Following vaccination with V114 or Prevnar 13™, the percentage of participants with solicited systemic AEs was assessed. The solicited systemic AEs assessed were muscle pain/myalgia, joint pain/arthralgia, headache, and tiredness/fatigue. Estimated CIs are calculated based on the exact binomial method proposed by Clopper and Pearson.</description>
        <time_frame>Up to 14 days after Vaccination 1</time_frame>
        <population>The analysis population included all randomized participants who received the relevant study vaccination for the timepoint of interest and were included in the intervention group according to the intervention they received. One participant in the Prevnar 13™ group incorrectly received V114 and was included in the V114 group for safety analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>V114</title>
            <description>Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
          <group group_id="O2">
            <title>Prevnar 13™</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Solicited Systemic Adverse Events Following V114 or Prevnar 13™</title>
          <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Following vaccination with V114 or Prevnar 13™, the percentage of participants with solicited systemic AEs was assessed. The solicited systemic AEs assessed were muscle pain/myalgia, joint pain/arthralgia, headache, and tiredness/fatigue. Estimated CIs are calculated based on the exact binomial method proposed by Clopper and Pearson.</description>
          <population>The analysis population included all randomized participants who received the relevant study vaccination for the timepoint of interest and were included in the intervention group according to the intervention they received. One participant in the Prevnar 13™ group incorrectly received V114 and was included in the V114 group for safety analyses.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1134"/>
                <count group_id="O2" value="378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Joint pain/arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" lower_limit="10.8" upper_limit="14.8"/>
                    <measurement group_id="O2" value="11.6" lower_limit="8.6" upper_limit="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tiredness/fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.3" lower_limit="31.5" upper_limit="37.1"/>
                    <measurement group_id="O2" value="36.8" lower_limit="31.9" upper_limit="41.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5" lower_limit="23.9" upper_limit="29.1"/>
                    <measurement group_id="O2" value="24.9" lower_limit="20.6" upper_limit="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain/myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.8" lower_limit="26.2" upper_limit="31.6"/>
                    <measurement group_id="O2" value="25.5" lower_limit="22.1" upper_limit="31.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Vaccine-related Serious Adverse Event Following V114 or Prevnar 13™</title>
        <description>A serious adverse event (SAE) is an AE that is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Relatedness of an SAE to the study vaccine was determined by the investigator. Following vaccination with V114 or Prevnar 13™, the percentage of serious adverse events of V114 compared with Prevnar 13™ was assessed. Estimated CIs are calculated based on the exact binomial method proposed by Clopper and Pearson.</description>
        <time_frame>Up to Month 6 (before Vaccination 2)</time_frame>
        <population>The analysis population included all randomized participants who received the relevant study vaccination for the timepoint of interest and were included in the intervention group according to the intervention they received. One participant in the Prevnar 13™ group incorrectly received V114 and was included in the V114 group for safety analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>V114</title>
            <description>Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
          <group group_id="O2">
            <title>Prevnar 13™</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Vaccine-related Serious Adverse Event Following V114 or Prevnar 13™</title>
          <description>A serious adverse event (SAE) is an AE that is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Relatedness of an SAE to the study vaccine was determined by the investigator. Following vaccination with V114 or Prevnar 13™, the percentage of serious adverse events of V114 compared with Prevnar 13™ was assessed. Estimated CIs are calculated based on the exact binomial method proposed by Clopper and Pearson.</description>
          <population>The analysis population included all randomized participants who received the relevant study vaccination for the timepoint of interest and were included in the intervention group according to the intervention they received. One participant in the Prevnar 13™ group incorrectly received V114 and was included in the V114 group for safety analyses.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1134"/>
                <count group_id="O2" value="378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer of Serotype-specific Opsonophagocytic Activity Day 30 Following V114 or Prevnar 13™</title>
        <description>The geometric mean titer (GMT) of serotype-specific opsonophagocytic activity (OPA) for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using a multiplex opsonophagocytic assay. The within-group 95% CIs are obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution.</description>
        <time_frame>Day 30</time_frame>
        <population>The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>V114</title>
            <description>Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
          <group group_id="O2">
            <title>Prevnar 13™</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer of Serotype-specific Opsonophagocytic Activity Day 30 Following V114 or Prevnar 13™</title>
          <description>The geometric mean titer (GMT) of serotype-specific opsonophagocytic activity (OPA) for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using a multiplex opsonophagocytic assay. The within-group 95% CIs are obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution.</description>
          <population>The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1133"/>
                <count group_id="O2" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1019"/>
                    <count group_id="O2" value="341"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="268.6" lower_limit="243.7" upper_limit="296.0"/>
                    <measurement group_id="O2" value="267.2" lower_limit="220.4" upper_limit="323.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1004"/>
                    <count group_id="O2" value="340"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199.3" lower_limit="184.6" upper_limit="215.2"/>
                    <measurement group_id="O2" value="150.6" lower_limit="130.6" upper_limit="173.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1016"/>
                    <count group_id="O2" value="342"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1416.0" lower_limit="1308.9" upper_limit="1531.8"/>
                    <measurement group_id="O2" value="2576.1" lower_limit="2278.0" upper_limit="2913.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1018"/>
                    <count group_id="O2" value="343"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="564.8" lower_limit="512.7" upper_limit="622.2"/>
                    <measurement group_id="O2" value="731.1" lower_limit="613.6" upper_limit="871.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1006"/>
                    <count group_id="O2" value="335"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12928.8" lower_limit="11923.4" upper_limit="14019.0"/>
                    <measurement group_id="O2" value="11282.4" lower_limit="9718.8" upper_limit="13097.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1014"/>
                    <count group_id="O2" value="342"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10336.9" lower_limit="9649.4" upper_limit="11073.4"/>
                    <measurement group_id="O2" value="6995.7" lower_limit="6024.7" upper_limit="8123.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1019"/>
                    <count group_id="O2" value="342"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5756.4" lower_limit="5410.4" upper_limit="6124.6"/>
                    <measurement group_id="O2" value="7588.9" lower_limit="6775.3" upper_limit="8500.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1015"/>
                    <count group_id="O2" value="343"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3355.1" lower_limit="3135.4" upper_limit="3590.1"/>
                    <measurement group_id="O2" value="3983.7" lower_limit="3557.8" upper_limit="4460.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1016"/>
                    <count group_id="O2" value="343"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5228.9" lower_limit="4847.6" upper_limit="5640.2"/>
                    <measurement group_id="O2" value="5889.8" lower_limit="5218.2" upper_limit="6647.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1014"/>
                    <count group_id="O2" value="343"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5709.0" lower_limit="5331.1" upper_limit="6113.6"/>
                    <measurement group_id="O2" value="3063.2" lower_limit="2699.8" upper_limit="3475.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1015"/>
                    <count group_id="O2" value="343"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5369.9" lower_limit="5017.7" upper_limit="5746.8"/>
                    <measurement group_id="O2" value="5888.0" lower_limit="5228.2" upper_limit="6631.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1018"/>
                    <count group_id="O2" value="343"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3266.3" lower_limit="3064.4" upper_limit="3481.4"/>
                    <measurement group_id="O2" value="3272.7" lower_limit="2948.2" upper_limit="3632.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1016"/>
                    <count group_id="O2" value="340"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4853.5" lower_limit="4469.8" upper_limit="5270.2"/>
                    <measurement group_id="O2" value="3887.3" lower_limit="3335.8" upper_limit="4530.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 22F (Unique to V114)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1005"/>
                    <count group_id="O2" value="320"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3926.5" lower_limit="3645.9" upper_limit="4228.7"/>
                    <measurement group_id="O2" value="291.6" lower_limit="221.8" upper_limit="383.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 33F (Unique to V114)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1014"/>
                    <count group_id="O2" value="338"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11627.8" lower_limit="10824.6" upper_limit="12490.7"/>
                    <measurement group_id="O2" value="2180.6" lower_limit="1828.7" upper_limit="2600.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Solicited Injection-site Adverse Events Following PNEUMOVAX™23</title>
        <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Following Vaccination 2 with PNEUMOVAX™23, the percentage of participants with solicited injection-site AEs was assessed. The solicited injection-site AEs assessed were redness/erythema, swelling, and tenderness/pain. Estimated CIs are calculated based on the exact binomial method proposed by Clopper and Pearson and are provided in accordance with the statistical analysis plan.</description>
        <time_frame>Up to 5 days after Vaccination 2 (Month 6)</time_frame>
        <population>All randomized participants who received the relevant study vaccination for the timepoint of interest and were included in the intervention group according to the intervention they received. One participant in the Prevnar 13™ group incorrectly received V114 and was included in the V114 group for safety analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>V114</title>
            <description>Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
          <group group_id="O2">
            <title>Prevnar 13™</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Solicited Injection-site Adverse Events Following PNEUMOVAX™23</title>
          <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Following Vaccination 2 with PNEUMOVAX™23, the percentage of participants with solicited injection-site AEs was assessed. The solicited injection-site AEs assessed were redness/erythema, swelling, and tenderness/pain. Estimated CIs are calculated based on the exact binomial method proposed by Clopper and Pearson and are provided in accordance with the statistical analysis plan.</description>
          <population>All randomized participants who received the relevant study vaccination for the timepoint of interest and were included in the intervention group according to the intervention they received. One participant in the Prevnar 13™ group incorrectly received V114 and was included in the V114 group for safety analyses.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1036"/>
                <count group_id="O2" value="345"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site redness/erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.6" lower_limit="20.1" upper_limit="25.3"/>
                    <measurement group_id="O2" value="25.5" lower_limit="21.0" upper_limit="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site tenderness/pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.8" lower_limit="65.9" upper_limit="71.6"/>
                    <measurement group_id="O2" value="67.0" lower_limit="61.7" upper_limit="71.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.4" lower_limit="26.7" upper_limit="32.3"/>
                    <measurement group_id="O2" value="32.2" lower_limit="27.3" upper_limit="37.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Solicited Systemic Adverse Events Following PNEUMOVAX™23</title>
        <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Following Vaccination 2 with PNEUMOVAX™23, the percentage of participants with solicited systemic AEs was assessed. The solicited systemic AEs assessed were muscle pain/myalgia, joint pain/arthralgia, headache, and tiredness/fatigue. Estimated CIs are calculated based on the exact binomial method proposed by Clopper and Pearson.</description>
        <time_frame>Up to 14 days after Vaccination 2 (Month 6)</time_frame>
        <population>The analysis population included all randomized participants who received the relevant study vaccination for the timepoint of interest and were included in the intervention group according to the intervention they received. One participant in the Prevnar 13™ group incorrectly received V114 and was included in the V114 group for safety analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>V114</title>
            <description>Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
          <group group_id="O2">
            <title>Prevnar 13™</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Solicited Systemic Adverse Events Following PNEUMOVAX™23</title>
          <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Following Vaccination 2 with PNEUMOVAX™23, the percentage of participants with solicited systemic AEs was assessed. The solicited systemic AEs assessed were muscle pain/myalgia, joint pain/arthralgia, headache, and tiredness/fatigue. Estimated CIs are calculated based on the exact binomial method proposed by Clopper and Pearson.</description>
          <population>The analysis population included all randomized participants who received the relevant study vaccination for the timepoint of interest and were included in the intervention group according to the intervention they received. One participant in the Prevnar 13™ group incorrectly received V114 and was included in the V114 group for safety analyses.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1036"/>
                <count group_id="O2" value="345"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Joint pain/arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" lower_limit="10.1" upper_limit="14.1"/>
                    <measurement group_id="O2" value="11.0" lower_limit="7.9" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tiredness/fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.1" lower_limit="27.3" upper_limit="33.0"/>
                    <measurement group_id="O2" value="30.7" lower_limit="25.9" upper_limit="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.2" lower_limit="18.8" upper_limit="23.9"/>
                    <measurement group_id="O2" value="21.2" lower_limit="17.0" upper_limit="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain/myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1" lower_limit="21.6" upper_limit="26.9"/>
                    <measurement group_id="O2" value="25.5" lower_limit="21.0" upper_limit="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Vaccine-related Serious Adverse Event Following PNEUMOVAX™23</title>
        <description>A serious adverse event (SAE) is an AE that is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Relatedness of an SAE to the study vaccine was determined by the investigator. Following vaccination with PNEUMOVAX™23, the percentage of serious adverse events of V114 compared with Prevnar 13™ was assessed. Estimated CIs are calculated based on the exact binomial method proposed by Clopper and Pearson.</description>
        <time_frame>From Month 6 (before Vaccination 2) to Month 7</time_frame>
        <population>The analysis population included all randomized participants who received the relevant study vaccination for the timepoint of interest and were included in the intervention group according to the intervention they received. One participant in the Prevnar 13™ group incorrectly received V114 and was included in the V114 group for safety analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>V114</title>
            <description>Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
          <group group_id="O2">
            <title>Prevnar 13™</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Vaccine-related Serious Adverse Event Following PNEUMOVAX™23</title>
          <description>A serious adverse event (SAE) is an AE that is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Relatedness of an SAE to the study vaccine was determined by the investigator. Following vaccination with PNEUMOVAX™23, the percentage of serious adverse events of V114 compared with Prevnar 13™ was assessed. Estimated CIs are calculated based on the exact binomial method proposed by Clopper and Pearson.</description>
          <population>The analysis population included all randomized participants who received the relevant study vaccination for the timepoint of interest and were included in the intervention group according to the intervention they received. One participant in the Prevnar 13™ group incorrectly received V114 and was included in the V114 group for safety analyses.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1036"/>
                <count group_id="O2" value="345"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.3"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.0" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentration of Serotype-specific Immunoglobulin G at Day 30</title>
        <description>The geometric mean concentration (GMC) of serotype-specific immunoglobulin G (IgG) for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using an electrochemiluminescence assay. The within-group 95% CIs are obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution.</description>
        <time_frame>Day 30</time_frame>
        <population>The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>V114</title>
            <description>Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
          <group group_id="O2">
            <title>Prevnar 13™</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration of Serotype-specific Immunoglobulin G at Day 30</title>
          <description>The geometric mean concentration (GMC) of serotype-specific immunoglobulin G (IgG) for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using an electrochemiluminescence assay. The within-group 95% CIs are obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution.</description>
          <population>The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1133"/>
                <count group_id="O2" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1020"/>
                    <count group_id="O2" value="343"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.56" lower_limit="3.29" upper_limit="3.85"/>
                    <measurement group_id="O2" value="4.59" lower_limit="4.00" upper_limit="5.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1017"/>
                    <count group_id="O2" value="343"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" lower_limit="0.72" upper_limit="0.83"/>
                    <measurement group_id="O2" value="0.63" lower_limit="0.57" upper_limit="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1015"/>
                    <count group_id="O2" value="343"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" lower_limit="1.40" upper_limit="1.66"/>
                    <measurement group_id="O2" value="2.71" lower_limit="2.34" upper_limit="3.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1020"/>
                    <count group_id="O2" value="342"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.43" lower_limit="3.14" upper_limit="3.75"/>
                    <measurement group_id="O2" value="4.48" lower_limit="3.77" upper_limit="5.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1020"/>
                    <count group_id="O2" value="343"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.84" lower_limit="10.71" upper_limit="13.10"/>
                    <measurement group_id="O2" value="10.87" lower_limit="9.06" upper_limit="13.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1020"/>
                    <count group_id="O2" value="342"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.90" lower_limit="16.21" upper_limit="19.76"/>
                    <measurement group_id="O2" value="11.36" lower_limit="9.45" upper_limit="13.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1020"/>
                    <count group_id="O2" value="343"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.18" lower_limit="4.77" upper_limit="5.62"/>
                    <measurement group_id="O2" value="6.88" lower_limit="5.95" upper_limit="7.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1019"/>
                    <count group_id="O2" value="343"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.44" lower_limit="4.11" upper_limit="4.80"/>
                    <measurement group_id="O2" value="5.31" lower_limit="4.62" upper_limit="6.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1020"/>
                    <count group_id="O2" value="343"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.91" lower_limit="14.46" upper_limit="17.51"/>
                    <measurement group_id="O2" value="17.35" lower_limit="14.93" upper_limit="20.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1020"/>
                    <count group_id="O2" value="343"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.57" lower_limit="13.42" upper_limit="15.81"/>
                    <measurement group_id="O2" value="9.32" lower_limit="8.06" upper_limit="10.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1020"/>
                    <count group_id="O2" value="343"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.41" lower_limit="18.00" upper_limit="20.93"/>
                    <measurement group_id="O2" value="21.79" lower_limit="18.85" upper_limit="25.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1018"/>
                    <count group_id="O2" value="343"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.98" lower_limit="12.90" upper_limit="15.14"/>
                    <measurement group_id="O2" value="13.35" lower_limit="11.52" upper_limit="15.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1019"/>
                    <count group_id="O2" value="343"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.57" lower_limit="12.44" upper_limit="14.80"/>
                    <measurement group_id="O2" value="10.98" lower_limit="9.34" upper_limit="12.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 22F (Unique to V114)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1020"/>
                    <count group_id="O2" value="342"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.22" lower_limit="5.74" upper_limit="6.74"/>
                    <measurement group_id="O2" value="0.52" lower_limit="0.45" upper_limit="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 33F (Unique to V114)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1020"/>
                    <count group_id="O2" value="342"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.79" lower_limit="7.16" upper_limit="8.48"/>
                    <measurement group_id="O2" value="0.88" lower_limit="0.78" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Rise in Serotype-specific OPA Day 1 to Day 30</title>
        <description>Activity for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using a Multiplex Opsonophagocytic Assay. Geometric mean fold rise (GMFR) is the geometric mean of fold rise from baseline to postvaccination.</description>
        <time_frame>Day 1 (Baseline) and Day 30</time_frame>
        <population>The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>V114</title>
            <description>Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
          <group group_id="O2">
            <title>Prevnar 13™</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rise in Serotype-specific OPA Day 1 to Day 30</title>
          <description>Activity for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using a Multiplex Opsonophagocytic Assay. Geometric mean fold rise (GMFR) is the geometric mean of fold rise from baseline to postvaccination.</description>
          <population>The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1133"/>
                <count group_id="O2" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1001"/>
                    <count group_id="O2" value="334"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.8" lower_limit="20.6" upper_limit="25.1"/>
                    <measurement group_id="O2" value="21.9" lower_limit="18.4" upper_limit="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="982"/>
                    <count group_id="O2" value="329"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" lower_limit="5.4" upper_limit="6.3"/>
                    <measurement group_id="O2" value="4.8" lower_limit="4.3" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="988"/>
                    <count group_id="O2" value="329"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9" lower_limit="16.2" upper_limit="19.8"/>
                    <measurement group_id="O2" value="33.4" lower_limit="28.1" upper_limit="39.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1003"/>
                    <count group_id="O2" value="337"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" lower_limit="15.7" upper_limit="18.9"/>
                    <measurement group_id="O2" value="21.1" lower_limit="18.0" upper_limit="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="910"/>
                    <count group_id="O2" value="298"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.7" lower_limit="19.6" upper_limit="23.9"/>
                    <measurement group_id="O2" value="21.4" lower_limit="18.0" upper_limit="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="969"/>
                    <count group_id="O2" value="328"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.2" lower_limit="28.6" upper_limit="36.3"/>
                    <measurement group_id="O2" value="25.0" lower_limit="20.6" upper_limit="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="945"/>
                    <count group_id="O2" value="318"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" lower_limit="6.6" upper_limit="8.2"/>
                    <measurement group_id="O2" value="10.0" lower_limit="8.3" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="977"/>
                    <count group_id="O2" value="332"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" lower_limit="4.5" upper_limit="5.3"/>
                    <measurement group_id="O2" value="5.7" lower_limit="5.0" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="973"/>
                    <count group_id="O2" value="331"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" lower_limit="7.4" upper_limit="9.2"/>
                    <measurement group_id="O2" value="8.7" lower_limit="7.2" upper_limit="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="973"/>
                    <count group_id="O2" value="331"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.4" lower_limit="18.6" upper_limit="22.4"/>
                    <measurement group_id="O2" value="11.7" lower_limit="10.1" upper_limit="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="975"/>
                    <count group_id="O2" value="326"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="11.3" upper_limit="13.9"/>
                    <measurement group_id="O2" value="13.6" lower_limit="11.4" upper_limit="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="985"/>
                    <count group_id="O2" value="329"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" lower_limit="6.9" upper_limit="8.2"/>
                    <measurement group_id="O2" value="7.4" lower_limit="6.4" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="945"/>
                    <count group_id="O2" value="310"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5" lower_limit="20.0" upper_limit="25.4"/>
                    <measurement group_id="O2" value="17.8" lower_limit="14.6" upper_limit="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 22F (Unique to V114)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="885"/>
                    <count group_id="O2" value="290"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9" lower_limit="11.8" upper_limit="16.3"/>
                    <measurement group_id="O2" value="1.3" lower_limit="1.1" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 33F (Unique to V114)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="979"/>
                    <count group_id="O2" value="326"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="4.9" upper_limit="5.9"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.8" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMFR in Serotype-specific IgG Day 1 to Day 30</title>
        <description>IgG for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using an electrochemiluminescence assay. GMFR is the geometric mean of fold rise from baseline to postvaccination.</description>
        <time_frame>Day 1 (Baseline) and Day 30</time_frame>
        <population>The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>V114</title>
            <description>Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
          <group group_id="O2">
            <title>Prevnar 13™</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
        </group_list>
        <measure>
          <title>GMFR in Serotype-specific IgG Day 1 to Day 30</title>
          <description>IgG for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using an electrochemiluminescence assay. GMFR is the geometric mean of fold rise from baseline to postvaccination.</description>
          <population>The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1133"/>
                <count group_id="O2" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1007"/>
                    <count group_id="O2" value="338"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" lower_limit="11.3" upper_limit="13.2"/>
                    <measurement group_id="O2" value="15.7" lower_limit="13.9" upper_limit="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1004"/>
                    <count group_id="O2" value="338"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="3.8" upper_limit="4.3"/>
                    <measurement group_id="O2" value="3.6" lower_limit="3.2" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1001"/>
                    <count group_id="O2" value="338"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="7.4" upper_limit="8.6"/>
                    <measurement group_id="O2" value="16.2" lower_limit="14.3" upper_limit="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1007"/>
                    <count group_id="O2" value="337"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="4.0" upper_limit="4.7"/>
                    <measurement group_id="O2" value="5.2" lower_limit="4.5" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1007"/>
                    <count group_id="O2" value="338"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.5" lower_limit="32.5" upper_limit="38.8"/>
                    <measurement group_id="O2" value="31.3" lower_limit="26.7" upper_limit="36.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1006"/>
                    <count group_id="O2" value="337"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.5" lower_limit="37.1" upper_limit="44.2"/>
                    <measurement group_id="O2" value="28.0" lower_limit="24.2" upper_limit="32.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1007"/>
                    <count group_id="O2" value="338"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" lower_limit="11.3" upper_limit="13.2"/>
                    <measurement group_id="O2" value="16.9" lower_limit="14.8" upper_limit="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1006"/>
                    <count group_id="O2" value="338"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" lower_limit="9.8" upper_limit="11.4"/>
                    <measurement group_id="O2" value="12.8" lower_limit="11.3" upper_limit="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1007"/>
                    <count group_id="O2" value="338"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" lower_limit="10.3" upper_limit="12.5"/>
                    <measurement group_id="O2" value="11.5" lower_limit="9.7" upper_limit="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1007"/>
                    <count group_id="O2" value="338"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.5" lower_limit="28.0" upper_limit="33.1"/>
                    <measurement group_id="O2" value="20.0" lower_limit="17.2" upper_limit="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1007"/>
                    <count group_id="O2" value="338"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="10.2" upper_limit="12.0"/>
                    <measurement group_id="O2" value="14.0" lower_limit="12.2" upper_limit="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1005"/>
                    <count group_id="O2" value="338"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4" lower_limit="13.2" upper_limit="15.7"/>
                    <measurement group_id="O2" value="15.3" lower_limit="13.1" upper_limit="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1006"/>
                    <count group_id="O2" value="338"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5" lower_limit="24.2" upper_limit="29.0"/>
                    <measurement group_id="O2" value="22.0" lower_limit="19.0" upper_limit="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 22F (Unique to V114)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1007"/>
                    <count group_id="O2" value="337"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" lower_limit="10.4" upper_limit="12.6"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 33F (Unique to V114)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1007"/>
                    <count group_id="O2" value="337"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" lower_limit="7.7" upper_limit="8.9"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With ≥4-Fold Rise in Serotype-specific OPA Day 1 to Day 30</title>
        <description>Activity for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using a Multiplexed Opsonophagocytic Assay. The percentage of participants who had ≥4-fold rise in OPA titers were calculated from baseline to postvaccination.</description>
        <time_frame>Day 1 (Baseline) and Day 30</time_frame>
        <population>The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>V114</title>
            <description>Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
          <group group_id="O2">
            <title>Prevnar 13™</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With ≥4-Fold Rise in Serotype-specific OPA Day 1 to Day 30</title>
          <description>Activity for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using a Multiplexed Opsonophagocytic Assay. The percentage of participants who had ≥4-fold rise in OPA titers were calculated from baseline to postvaccination.</description>
          <population>The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1133"/>
                <count group_id="O2" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1001"/>
                    <count group_id="O2" value="334"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.9" lower_limit="81.5" upper_limit="86.1"/>
                    <measurement group_id="O2" value="81.4" lower_limit="76.8" upper_limit="85.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="982"/>
                    <count group_id="O2" value="329"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.2" lower_limit="59.1" upper_limit="65.3"/>
                    <measurement group_id="O2" value="56.8" lower_limit="51.3" upper_limit="62.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="988"/>
                    <count group_id="O2" value="329"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.0" lower_limit="76.4" upper_limit="81.5"/>
                    <measurement group_id="O2" value="87.8" lower_limit="83.8" upper_limit="91.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1003"/>
                    <count group_id="O2" value="337"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.4" lower_limit="81.0" upper_limit="85.7"/>
                    <measurement group_id="O2" value="84.9" lower_limit="80.6" upper_limit="88.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="910"/>
                    <count group_id="O2" value="298"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5" lower_limit="85.1" upper_limit="89.6"/>
                    <measurement group_id="O2" value="85.2" lower_limit="80.7" upper_limit="89.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="969"/>
                    <count group_id="O2" value="328"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.7" lower_limit="82.3" upper_limit="86.9"/>
                    <measurement group_id="O2" value="83.8" lower_limit="79.4" upper_limit="87.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="945"/>
                    <count group_id="O2" value="318"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.8" lower_limit="53.6" upper_limit="60.0"/>
                    <measurement group_id="O2" value="64.5" lower_limit="58.9" upper_limit="69.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="977"/>
                    <count group_id="O2" value="332"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.5" lower_limit="48.3" upper_limit="54.7"/>
                    <measurement group_id="O2" value="55.4" lower_limit="49.0" upper_limit="60.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="973"/>
                    <count group_id="O2" value="331"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.8" lower_limit="56.7" upper_limit="62.9"/>
                    <measurement group_id="O2" value="60.4" lower_limit="54.9" upper_limit="65.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="973"/>
                    <count group_id="O2" value="331"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.5" lower_limit="82.1" upper_limit="86.7"/>
                    <measurement group_id="O2" value="75.8" lower_limit="70.8" upper_limit="80.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="975"/>
                    <count group_id="O2" value="326"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.1" lower_limit="69.2" upper_limit="74.9"/>
                    <measurement group_id="O2" value="75.2" lower_limit="70.1" upper_limit="79.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="985"/>
                    <count group_id="O2" value="329"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.3" lower_limit="61.2" upper_limit="67.3"/>
                    <measurement group_id="O2" value="65.7" lower_limit="60.2" upper_limit="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="945"/>
                    <count group_id="O2" value="310"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.7" lower_limit="76.0" upper_limit="81.3"/>
                    <measurement group_id="O2" value="77.7" lower_limit="72.7" upper_limit="82.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 22F (Unique to V114)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="885"/>
                    <count group_id="O2" value="290"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.9" lower_limit="55.5" upper_limit="62.1"/>
                    <measurement group_id="O2" value="15.5" lower_limit="11.5" upper_limit="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 33F (Unique to V114)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="979"/>
                    <count group_id="O2" value="326"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.9" lower_limit="49.7" upper_limit="56.1"/>
                    <measurement group_id="O2" value="3.1" lower_limit="1.5" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With ≥4-Fold Rise in Serotype-specific IgG Day 1 to Day 30</title>
        <description>IgG for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using an electrochemiluminescence assay. The percentage of participants who had ≥ 4-fold rise in IgG concentration are calculated from baseline to postvaccination.</description>
        <time_frame>Day 1 (Baseline) and Day 30</time_frame>
        <population>The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>V114</title>
            <description>Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
          <group group_id="O2">
            <title>Prevnar 13™</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With ≥4-Fold Rise in Serotype-specific IgG Day 1 to Day 30</title>
          <description>IgG for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using an electrochemiluminescence assay. The percentage of participants who had ≥ 4-fold rise in IgG concentration are calculated from baseline to postvaccination.</description>
          <population>The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1133"/>
                <count group_id="O2" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1007"/>
                    <count group_id="O2" value="338"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.2" lower_limit="78.7" upper_limit="83.6"/>
                    <measurement group_id="O2" value="86.4" lower_limit="82.3" upper_limit="89.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1004"/>
                    <count group_id="O2" value="338"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.8" lower_limit="41.7" upper_limit="48.0"/>
                    <measurement group_id="O2" value="41.1" lower_limit="35.8" upper_limit="46.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1001"/>
                    <count group_id="O2" value="338"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.1" lower_limit="67.2" upper_limit="73.0"/>
                    <measurement group_id="O2" value="86.1" lower_limit="81.9" upper_limit="89.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1007"/>
                    <count group_id="O2" value="337"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.1" lower_limit="41.0" upper_limit="47.2"/>
                    <measurement group_id="O2" value="50.4" lower_limit="45.0" upper_limit="55.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1007"/>
                    <count group_id="O2" value="338"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3" lower_limit="91.6" upper_limit="94.8"/>
                    <measurement group_id="O2" value="88.2" lower_limit="84.2" upper_limit="91.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1006"/>
                    <count group_id="O2" value="337"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.4" lower_limit="91.7" upper_limit="94.9"/>
                    <measurement group_id="O2" value="90.5" lower_limit="86.9" upper_limit="93.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1007"/>
                    <count group_id="O2" value="338"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.3" lower_limit="76.7" upper_limit="81.8"/>
                    <measurement group_id="O2" value="86.4" lower_limit="82.3" upper_limit="89.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1006"/>
                    <count group_id="O2" value="338"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.5" lower_limit="73.8" upper_limit="79.1"/>
                    <measurement group_id="O2" value="84.0" lower_limit="79.7" upper_limit="87.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1007"/>
                    <count group_id="O2" value="338"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.8" lower_limit="67.9" upper_limit="73.6"/>
                    <measurement group_id="O2" value="68.6" lower_limit="63.4" upper_limit="73.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1007"/>
                    <count group_id="O2" value="338"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.1" lower_limit="89.1" upper_limit="92.8"/>
                    <measurement group_id="O2" value="87.3" lower_limit="83.2" upper_limit="90.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1007"/>
                    <count group_id="O2" value="338"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.3" lower_limit="72.5" upper_limit="77.9"/>
                    <measurement group_id="O2" value="82.0" lower_limit="77.4" upper_limit="85.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1005"/>
                    <count group_id="O2" value="338"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" lower_limit="77.4" upper_limit="82.4"/>
                    <measurement group_id="O2" value="80.8" lower_limit="76.2" upper_limit="84.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1006"/>
                    <count group_id="O2" value="338"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.2" lower_limit="87.1" upper_limit="91.0"/>
                    <measurement group_id="O2" value="87.6" lower_limit="83.6" upper_limit="90.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 22F (Unique to V114)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1007"/>
                    <count group_id="O2" value="337"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.1" lower_limit="70.2" upper_limit="75.8"/>
                    <measurement group_id="O2" value="1.5" lower_limit="0.5" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 33F (Unique to V114)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1007"/>
                    <count group_id="O2" value="337"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0" lower_limit="67.1" upper_limit="72.8"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.0" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer of Serotype-specific OPA at Month 7</title>
        <description>The geometric mean titer (GMT) of serotype-specific OPA for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using a multiplex opsonophagocytic assay. The within-group 95% CIs are obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution.</description>
        <time_frame>Month 7</time_frame>
        <population>The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>V114</title>
            <description>Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
          <group group_id="O2">
            <title>Prevnar 13™</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer of Serotype-specific OPA at Month 7</title>
          <description>The geometric mean titer (GMT) of serotype-specific OPA for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using a multiplex opsonophagocytic assay. The within-group 95% CIs are obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution.</description>
          <population>The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1133"/>
                <count group_id="O2" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="841"/>
                    <count group_id="O2" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="266.6" lower_limit="243.6" upper_limit="291.8"/>
                    <measurement group_id="O2" value="214.4" lower_limit="180.7" upper_limit="254.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="837"/>
                    <count group_id="O2" value="279"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="211.0" lower_limit="195.2" upper_limit="228.1"/>
                    <measurement group_id="O2" value="208.0" lower_limit="179.7" upper_limit="240.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="840"/>
                    <count group_id="O2" value="283"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1734.5" lower_limit="1620.7" upper_limit="1856.4"/>
                    <measurement group_id="O2" value="1980.6" lower_limit="1771.3" upper_limit="2214.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="844"/>
                    <count group_id="O2" value="283"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="595.1" lower_limit="544.5" upper_limit="650.5"/>
                    <measurement group_id="O2" value="626.7" lower_limit="531.7" upper_limit="738.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="830"/>
                    <count group_id="O2" value="276"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5810.3" lower_limit="5366.9" upper_limit="6290.3"/>
                    <measurement group_id="O2" value="5739.9" lower_limit="4974.4" upper_limit="6623.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="843"/>
                    <count group_id="O2" value="283"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5215.2" lower_limit="4863.6" upper_limit="5592.2"/>
                    <measurement group_id="O2" value="4412.4" lower_limit="3892.8" upper_limit="5001.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="843"/>
                    <count group_id="O2" value="283"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6070.5" lower_limit="5699.7" upper_limit="6465.6"/>
                    <measurement group_id="O2" value="6223.9" lower_limit="5595.3" upper_limit="6923.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="842"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3133.1" lower_limit="2918.4" upper_limit="3363.7"/>
                    <measurement group_id="O2" value="3364.1" lower_limit="2972.2" upper_limit="3807.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="843"/>
                    <count group_id="O2" value="283"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5644.9" lower_limit="5262.5" upper_limit="6055.2"/>
                    <measurement group_id="O2" value="5317.6" lower_limit="4686.1" upper_limit="6034.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="842"/>
                    <count group_id="O2" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3260.6" lower_limit="3057.3" upper_limit="3477.5"/>
                    <measurement group_id="O2" value="2294.4" lower_limit="2052.5" upper_limit="2564.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="836"/>
                    <count group_id="O2" value="283"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4336.2" lower_limit="4038.6" upper_limit="4655.6"/>
                    <measurement group_id="O2" value="4286.4" lower_limit="3838.6" upper_limit="4786.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="844"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3198.6" lower_limit="3011.0" upper_limit="3397.8"/>
                    <measurement group_id="O2" value="3085.4" lower_limit="2770.7" upper_limit="3435.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="839"/>
                    <count group_id="O2" value="283"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3057.3" lower_limit="2823.0" upper_limit="3311.0"/>
                    <measurement group_id="O2" value="2896.0" lower_limit="2494.1" upper_limit="3362.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 22F (Unique to V114)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="837"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3624.0" lower_limit="3384.5" upper_limit="3880.3"/>
                    <measurement group_id="O2" value="4060.2" lower_limit="3358.6" upper_limit="4908.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 33F (Unique to V114)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="837"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11356.6" lower_limit="10492.4" upper_limit="12291.9"/>
                    <measurement group_id="O2" value="16053.2" lower_limit="13688.1" upper_limit="18827.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentration of Serotype-specific IgG at Month 7</title>
        <description>The geometric mean concentration (GMC) of serotype-specific immunoglobulin G (IgG) for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using an electrochemiluminescence assay.</description>
        <time_frame>Month 7</time_frame>
        <population>The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>V114</title>
            <description>Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
          <group group_id="O2">
            <title>Prevnar 13™</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration of Serotype-specific IgG at Month 7</title>
          <description>The geometric mean concentration (GMC) of serotype-specific immunoglobulin G (IgG) for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using an electrochemiluminescence assay.</description>
          <population>The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1133"/>
                <count group_id="O2" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="844"/>
                    <count group_id="O2" value="283"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.91" lower_limit="2.71" upper_limit="3.12"/>
                    <measurement group_id="O2" value="3.42" lower_limit="3.02" upper_limit="3.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="844"/>
                    <count group_id="O2" value="283"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" lower_limit="0.62" upper_limit="0.71"/>
                    <measurement group_id="O2" value="0.68" lower_limit="0.61" upper_limit="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="843"/>
                    <count group_id="O2" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" lower_limit="1.23" upper_limit="1.44"/>
                    <measurement group_id="O2" value="1.77" lower_limit="1.55" upper_limit="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="844"/>
                    <count group_id="O2" value="283"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.45" lower_limit="3.17" upper_limit="3.75"/>
                    <measurement group_id="O2" value="3.92" lower_limit="3.37" upper_limit="4.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="843"/>
                    <count group_id="O2" value="283"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.25" lower_limit="3.84" upper_limit="4.69"/>
                    <measurement group_id="O2" value="4.88" lower_limit="4.08" upper_limit="5.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="844"/>
                    <count group_id="O2" value="283"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.79" lower_limit="6.15" upper_limit="7.49"/>
                    <measurement group_id="O2" value="6.04" lower_limit="5.08" upper_limit="7.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="844"/>
                    <count group_id="O2" value="283"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.46" lower_limit="3.36" upper_limit="3.94"/>
                    <measurement group_id="O2" value="4.07" lower_limit="3.54" upper_limit="4.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="844"/>
                    <count group_id="O2" value="283"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.18" lower_limit="2.96" upper_limit="3.43"/>
                    <measurement group_id="O2" value="3.61" lower_limit="3.17" upper_limit="4.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="844"/>
                    <count group_id="O2" value="283"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.28" lower_limit="13.13" upper_limit="15.53"/>
                    <measurement group_id="O2" value="14.59" lower_limit="12.64" upper_limit="16.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="844"/>
                    <count group_id="O2" value="283"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.50" lower_limit="5.07" upper_limit="5.98"/>
                    <measurement group_id="O2" value="4.24" lower_limit="3.71" upper_limit="4.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="844"/>
                    <count group_id="O2" value="283"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.26" lower_limit="10.47" upper_limit="12.11"/>
                    <measurement group_id="O2" value="12.04" lower_limit="10.57" upper_limit="13.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="844"/>
                    <count group_id="O2" value="283"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.07" lower_limit="8.45" upper_limit="9.74"/>
                    <measurement group_id="O2" value="8.81" lower_limit="7.74" upper_limit="10.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="844"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.42" lower_limit="4.98" upper_limit="5.89"/>
                    <measurement group_id="O2" value="4.96" lower_limit="4.25" upper_limit="5.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 22F (Unique to V114)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="844"/>
                    <count group_id="O2" value="283"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.85" lower_limit="4.50" upper_limit="5.23"/>
                    <measurement group_id="O2" value="4.76" lower_limit="4.01" upper_limit="5.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 33F (Unique to V114)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="844"/>
                    <count group_id="O2" value="283"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.98" lower_limit="5.50" upper_limit="6.50"/>
                    <measurement group_id="O2" value="8.66" lower_limit="7.31" upper_limit="10.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMFR in Serotype-specific OPA Day 1 to Month 7</title>
        <description>Activity for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using a Multiplexed Opsonophagocytic Assay. Geometric mean fold rise (GMFR) is the geometric mean of fold rise from baseline to postvaccination.</description>
        <time_frame>Day 1 (Baseline) and Month 7</time_frame>
        <population>The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>V114</title>
            <description>Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
          <group group_id="O2">
            <title>Prevnar 13™</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
        </group_list>
        <measure>
          <title>GMFR in Serotype-specific OPA Day 1 to Month 7</title>
          <description>Activity for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using a Multiplexed Opsonophagocytic Assay. Geometric mean fold rise (GMFR) is the geometric mean of fold rise from baseline to postvaccination.</description>
          <population>The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1133"/>
                <count group_id="O2" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="826"/>
                    <count group_id="O2" value="276"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.6" lower_limit="20.6" upper_limit="24.8"/>
                    <measurement group_id="O2" value="17.4" lower_limit="14.8" upper_limit="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="820"/>
                    <count group_id="O2" value="270"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" lower_limit="5.6" upper_limit="6.6"/>
                    <measurement group_id="O2" value="6.4" lower_limit="5.6" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="820"/>
                    <count group_id="O2" value="273"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6" lower_limit="19.5" upper_limit="23.9"/>
                    <measurement group_id="O2" value="25.6" lower_limit="21.7" upper_limit="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="831"/>
                    <count group_id="O2" value="279"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8" lower_limit="16.3" upper_limit="19.3"/>
                    <measurement group_id="O2" value="18.3" lower_limit="15.8" upper_limit="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="754"/>
                    <count group_id="O2" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" lower_limit="8.7" upper_limit="10.5"/>
                    <measurement group_id="O2" value="11.0" lower_limit="9.3" upper_limit="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="802"/>
                    <count group_id="O2" value="273"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.6" lower_limit="14.7" upper_limit="18.7"/>
                    <measurement group_id="O2" value="15.7" lower_limit="12.8" upper_limit="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="777"/>
                    <count group_id="O2" value="264"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" lower_limit="6.9" upper_limit="8.6"/>
                    <measurement group_id="O2" value="8.2" lower_limit="6.7" upper_limit="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="810"/>
                    <count group_id="O2" value="273"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="4.2" upper_limit="4.9"/>
                    <measurement group_id="O2" value="4.9" lower_limit="4.2" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="809"/>
                    <count group_id="O2" value="275"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" lower_limit="8.2" upper_limit="10.3"/>
                    <measurement group_id="O2" value="8.0" lower_limit="6.6" upper_limit="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="805"/>
                    <count group_id="O2" value="273"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="10.2" upper_limit="12.2"/>
                    <measurement group_id="O2" value="9.1" lower_limit="7.9" upper_limit="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="806"/>
                    <count group_id="O2" value="271"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" lower_limit="8.6" upper_limit="10.6"/>
                    <measurement group_id="O2" value="9.7" lower_limit="8.1" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="818"/>
                    <count group_id="O2" value="272"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" lower_limit="6.3" upper_limit="7.6"/>
                    <measurement group_id="O2" value="7.1" lower_limit="6.1" upper_limit="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="780"/>
                    <count group_id="O2" value="260"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" lower_limit="12.4" upper_limit="15.7"/>
                    <measurement group_id="O2" value="12.6" lower_limit="10.3" upper_limit="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 22F (Unique to V114)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="742"/>
                    <count group_id="O2" value="254"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" lower_limit="10.4" upper_limit="14.3"/>
                    <measurement group_id="O2" value="16.6" lower_limit="12.2" upper_limit="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 33F (Unique to V114)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="810"/>
                    <count group_id="O2" value="273"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="4.6" upper_limit="5.7"/>
                    <measurement group_id="O2" value="6.6" lower_limit="5.5" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMFR in Serotype-specific IgG Day 1 to Month 7</title>
        <description>IgG for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using an electrochemiluminescence assay. GMFR is the geometric mean of fold rise from baseline to postvaccination.</description>
        <time_frame>Day 1 (Baseline) and Month 7</time_frame>
        <population>The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>V114</title>
            <description>Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
          <group group_id="O2">
            <title>Prevnar 13™</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
        </group_list>
        <measure>
          <title>GMFR in Serotype-specific IgG Day 1 to Month 7</title>
          <description>IgG for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using an electrochemiluminescence assay. GMFR is the geometric mean of fold rise from baseline to postvaccination.</description>
          <population>The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1133"/>
                <count group_id="O2" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="833"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" lower_limit="9.4" upper_limit="10.8"/>
                    <measurement group_id="O2" value="11.4" lower_limit="10.1" upper_limit="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="833"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="3.3" upper_limit="3.7"/>
                    <measurement group_id="O2" value="3.8" lower_limit="3.4" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="830"/>
                    <count group_id="O2" value="278"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="6.7" upper_limit="7.6"/>
                    <measurement group_id="O2" value="10.7" lower_limit="9.5" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="833"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="4.0" upper_limit="4.6"/>
                    <measurement group_id="O2" value="4.6" lower_limit="4.1" upper_limit="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="832"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" lower_limit="11.3" upper_limit="13.4"/>
                    <measurement group_id="O2" value="13.9" lower_limit="12.0" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="832"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3" lower_limit="14.1" upper_limit="16.6"/>
                    <measurement group_id="O2" value="14.9" lower_limit="13.0" upper_limit="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="833"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" lower_limit="8.1" upper_limit="9.3"/>
                    <measurement group_id="O2" value="10.1" lower_limit="9.0" upper_limit="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="833"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" lower_limit="7.1" upper_limit="8.1"/>
                    <measurement group_id="O2" value="8.5" lower_limit="7.6" upper_limit="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="833"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" lower_limit="9.4" upper_limit="11.3"/>
                    <measurement group_id="O2" value="10.0" lower_limit="8.5" upper_limit="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="833"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" lower_limit="10.7" upper_limit="12.4"/>
                    <measurement group_id="O2" value="9.3" lower_limit="8.2" upper_limit="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="833"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" lower_limit="6.0" upper_limit="6.9"/>
                    <measurement group_id="O2" value="7.5" lower_limit="6.7" upper_limit="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="833"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" lower_limit="8.3" upper_limit="9.7"/>
                    <measurement group_id="O2" value="9.8" lower_limit="8.6" upper_limit="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="833"/>
                    <count group_id="O2" value="279"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" lower_limit="9.9" upper_limit="11.7"/>
                    <measurement group_id="O2" value="10.3" lower_limit="9.0" upper_limit="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 22F (Unique to V114)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="833"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" lower_limit="8.1" upper_limit="9.7"/>
                    <measurement group_id="O2" value="8.9" lower_limit="7.5" upper_limit="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 33F (Unique to V114)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="833"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" lower_limit="6.0" upper_limit="6.9"/>
                    <measurement group_id="O2" value="9.6" lower_limit="8.4" upper_limit="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With ≥4-Fold Rise in Serotype-specific OPA Day 1 to Month 7</title>
        <description>Activity for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using a Multiplexed Opsonophagocytic Assay. The percentage of participants who had ≥4-fold rise in OPA titers were calculated from baseline to postvaccination.</description>
        <time_frame>Day 1 (Baseline) and Month 7</time_frame>
        <population>The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>V114</title>
            <description>Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
          <group group_id="O2">
            <title>Prevnar 13™</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With ≥4-Fold Rise in Serotype-specific OPA Day 1 to Month 7</title>
          <description>Activity for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using a Multiplexed Opsonophagocytic Assay. The percentage of participants who had ≥4-fold rise in OPA titers were calculated from baseline to postvaccination.</description>
          <population>The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1133"/>
                <count group_id="O2" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="826"/>
                    <count group_id="O2" value="276"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.7" lower_limit="85.2" upper_limit="89.8"/>
                    <measurement group_id="O2" value="83.7" lower_limit="78.8" upper_limit="87.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="820"/>
                    <count group_id="O2" value="270"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.5" lower_limit="63.1" upper_limit="69.7"/>
                    <measurement group_id="O2" value="66.7" lower_limit="60.7" upper_limit="72.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="820"/>
                    <count group_id="O2" value="273"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.3" lower_limit="81.6" upper_limit="86.7"/>
                    <measurement group_id="O2" value="86.4" lower_limit="81.8" upper_limit="90.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="831"/>
                    <count group_id="O2" value="279"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.8" lower_limit="84.3" upper_limit="89.0"/>
                    <measurement group_id="O2" value="87.1" lower_limit="82.6" upper_limit="90.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="754"/>
                    <count group_id="O2" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.5" lower_limit="70.2" upper_limit="76.6"/>
                    <measurement group_id="O2" value="80.2" lower_limit="74.6" upper_limit="84.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="802"/>
                    <count group_id="O2" value="273"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.8" lower_limit="72.7" upper_limit="78.7"/>
                    <measurement group_id="O2" value="74.4" lower_limit="68.7" upper_limit="79.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="777"/>
                    <count group_id="O2" value="264"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.8" lower_limit="56.3" upper_limit="63.3"/>
                    <measurement group_id="O2" value="60.2" lower_limit="54.0" upper_limit="66.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="810"/>
                    <count group_id="O2" value="273"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.5" lower_limit="47.0" upper_limit="54.0"/>
                    <measurement group_id="O2" value="52.4" lower_limit="46.3" upper_limit="58.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="809"/>
                    <count group_id="O2" value="275"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.9" lower_limit="61.5" upper_limit="68.2"/>
                    <measurement group_id="O2" value="58.9" lower_limit="52.8" upper_limit="64.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="805"/>
                    <count group_id="O2" value="273"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.5" lower_limit="74.5" upper_limit="80.4"/>
                    <measurement group_id="O2" value="76.2" lower_limit="70.7" upper_limit="81.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="806"/>
                    <count group_id="O2" value="271"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.2" lower_limit="64.9" upper_limit="71.4"/>
                    <measurement group_id="O2" value="70.5" lower_limit="64.7" upper_limit="75.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="818"/>
                    <count group_id="O2" value="272"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.0" lower_limit="57.6" upper_limit="64.4"/>
                    <measurement group_id="O2" value="62.9" lower_limit="56.8" upper_limit="68.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="780"/>
                    <count group_id="O2" value="260"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.5" lower_limit="70.2" upper_limit="76.5"/>
                    <measurement group_id="O2" value="71.9" lower_limit="66.0" upper_limit="77.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 22F (Unique to V114)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="742"/>
                    <count group_id="O2" value="254"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.0" lower_limit="55.4" upper_limit="62.6"/>
                    <measurement group_id="O2" value="65.4" lower_limit="59.2" upper_limit="71.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 33F (Unique to V114)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="810"/>
                    <count group_id="O2" value="273"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.3" lower_limit="49.8" upper_limit="56.8"/>
                    <measurement group_id="O2" value="60.8" lower_limit="54.7" upper_limit="66.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With ≥4-Fold Rise in Serotype-specific IgG Day 1 to Month 7</title>
        <description>IgG for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using an electrochemiluminescence assay. The percentage of participants who had ≥ 4-fold rise in IgG concentration are calculated from baseline to postvaccination.</description>
        <time_frame>Day 1 (Baseline) and Month 7</time_frame>
        <population>The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>V114</title>
            <description>Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
          <group group_id="O2">
            <title>Prevnar 13™</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With ≥4-Fold Rise in Serotype-specific IgG Day 1 to Month 7</title>
          <description>IgG for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using an electrochemiluminescence assay. The percentage of participants who had ≥ 4-fold rise in IgG concentration are calculated from baseline to postvaccination.</description>
          <population>The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1133"/>
                <count group_id="O2" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="833"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.4" lower_limit="78.6" upper_limit="84.0"/>
                    <measurement group_id="O2" value="83.6" lower_limit="78.7" upper_limit="87.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="833"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.7" lower_limit="37.3" upper_limit="44.1"/>
                    <measurement group_id="O2" value="46.1" lower_limit="40.1" upper_limit="52.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="830"/>
                    <count group_id="O2" value="278"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.2" lower_limit="68.0" upper_limit="74.3"/>
                    <measurement group_id="O2" value="82.0" lower_limit="77.0" upper_limit="86.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="833"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.7" lower_limit="45.3" upper_limit="52.2"/>
                    <measurement group_id="O2" value="51.8" lower_limit="45.8" upper_limit="57.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="832"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.6" lower_limit="78.8" upper_limit="84.2"/>
                    <measurement group_id="O2" value="81.8" lower_limit="76.8" upper_limit="86.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="832"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.4" lower_limit="83.9" upper_limit="88.7"/>
                    <measurement group_id="O2" value="85.4" lower_limit="80.7" upper_limit="89.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="833"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.4" lower_limit="74.4" upper_limit="80.2"/>
                    <measurement group_id="O2" value="84.3" lower_limit="79.5" upper_limit="88.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="833"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.8" lower_limit="68.6" upper_limit="74.8"/>
                    <measurement group_id="O2" value="77.1" lower_limit="71.8" upper_limit="81.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="833"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.7" lower_limit="73.7" upper_limit="79.5"/>
                    <measurement group_id="O2" value="70.7" lower_limit="65.0" upper_limit="76.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="833"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.7" lower_limit="80.0" upper_limit="85.2"/>
                    <measurement group_id="O2" value="80.4" lower_limit="75.2" upper_limit="84.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="833"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.8" lower_limit="62.5" upper_limit="69.0"/>
                    <measurement group_id="O2" value="74.6" lower_limit="69.1" upper_limit="79.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="833"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.5" lower_limit="71.4" upper_limit="77.5"/>
                    <measurement group_id="O2" value="78.9" lower_limit="73.7" upper_limit="83.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="833"/>
                    <count group_id="O2" value="279"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8" lower_limit="74.8" upper_limit="80.6"/>
                    <measurement group_id="O2" value="78.1" lower_limit="72.8" upper_limit="82.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 22F (Unique to V114)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="833"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.8" lower_limit="65.5" upper_limit="71.9"/>
                    <measurement group_id="O2" value="65.7" lower_limit="59.8" upper_limit="71.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 33F (Unique to V114)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="833"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.2" lower_limit="64.9" upper_limit="71.3"/>
                    <measurement group_id="O2" value="75.7" lower_limit="70.3" upper_limit="80.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMFR in Serotype-specific OPA Month 6 to Month 7</title>
        <description>Activity for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using the Multiplexed Opsonophagocytic Assay. Geometric mean fold rise (GMFR) is the geometric mean of fold rise from baseline to postvaccination.</description>
        <time_frame>Month 6 (Baseline before Vaccination 2) and Month 7</time_frame>
        <population>The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>V114</title>
            <description>Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
          <group group_id="O2">
            <title>Prevnar 13™</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
        </group_list>
        <measure>
          <title>GMFR in Serotype-specific OPA Month 6 to Month 7</title>
          <description>Activity for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using the Multiplexed Opsonophagocytic Assay. Geometric mean fold rise (GMFR) is the geometric mean of fold rise from baseline to postvaccination.</description>
          <population>The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1133"/>
                <count group_id="O2" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="839"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="2.9" upper_limit="3.5"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.7" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="826"/>
                    <count group_id="O2" value="274"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.9" upper_limit="2.1"/>
                    <measurement group_id="O2" value="2.4" lower_limit="2.2" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="837"/>
                    <count group_id="O2" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="2.5" upper_limit="2.9"/>
                    <measurement group_id="O2" value="1.7" lower_limit="1.5" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="840"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="2.5" upper_limit="2.9"/>
                    <measurement group_id="O2" value="2.1" lower_limit="1.9" upper_limit="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="818"/>
                    <count group_id="O2" value="270"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="1.1"/>
                    <measurement group_id="O2" value="1.1" lower_limit="1.0" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="842"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="1.1" upper_limit="1.2"/>
                    <measurement group_id="O2" value="1.2" lower_limit="1.1" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="837"/>
                    <count group_id="O2" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="1.8" upper_limit="2.0"/>
                    <measurement group_id="O2" value="1.4" lower_limit="1.3" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="835"/>
                    <count group_id="O2" value="278"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="1.5" upper_limit="1.7"/>
                    <measurement group_id="O2" value="1.5" lower_limit="1.4" upper_limit="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="841"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.8" upper_limit="2.1"/>
                    <measurement group_id="O2" value="1.5" lower_limit="1.3" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="839"/>
                    <count group_id="O2" value="279"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="1.3" upper_limit="1.4"/>
                    <measurement group_id="O2" value="1.6" lower_limit="1.4" upper_limit="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="830"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.6" upper_limit="1.8"/>
                    <measurement group_id="O2" value="1.5" lower_limit="1.4" upper_limit="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="843"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="1.8" upper_limit="2.0"/>
                    <measurement group_id="O2" value="1.6" lower_limit="1.5" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="837"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="1.2" upper_limit="1.4"/>
                    <measurement group_id="O2" value="1.4" lower_limit="1.2" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 22F (Unique to V114)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="822"/>
                    <count group_id="O2" value="253"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="1.7" upper_limit="1.9"/>
                    <measurement group_id="O2" value="9.6" lower_limit="7.1" upper_limit="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 33F (Unique to V114)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="834"/>
                    <count group_id="O2" value="278"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="1.5" upper_limit="1.8"/>
                    <measurement group_id="O2" value="6.5" lower_limit="5.5" upper_limit="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMFR in Serotype-specific IgG Month 6 to Month 7</title>
        <description>IgG for the serotypes contained in Prevnar 13™ and V114 and (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using an electrochemiluminescence assay. GMFR is the geometric mean of fold rise from baseline to postvaccination.</description>
        <time_frame>Month 6 (Baseline before Vaccination 2) and Month 7</time_frame>
        <population>The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>V114</title>
            <description>Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
          <group group_id="O2">
            <title>Prevnar 13™</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
        </group_list>
        <measure>
          <title>GMFR in Serotype-specific IgG Month 6 to Month 7</title>
          <description>IgG for the serotypes contained in Prevnar 13™ and V114 and (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using an electrochemiluminescence assay. GMFR is the geometric mean of fold rise from baseline to postvaccination.</description>
          <population>The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1133"/>
                <count group_id="O2" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="843"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="2.0" upper_limit="2.2"/>
                    <measurement group_id="O2" value="1.5" lower_limit="1.4" upper_limit="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="842"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.6" upper_limit="1.7"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.8" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="840"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.9" upper_limit="2.1"/>
                    <measurement group_id="O2" value="1.6" lower_limit="1.5" upper_limit="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="843"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="1.8" upper_limit="1.9"/>
                    <measurement group_id="O2" value="1.5" lower_limit="1.4" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="842"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="843"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="1.0" upper_limit="1.1"/>
                    <measurement group_id="O2" value="1.2" lower_limit="1.2" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="843"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.6" upper_limit="1.8"/>
                    <measurement group_id="O2" value="1.4" lower_limit="1.3" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="841"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1.5" upper_limit="1.6"/>
                    <measurement group_id="O2" value="1.4" lower_limit="1.3" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="843"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.6" upper_limit="1.8"/>
                    <measurement group_id="O2" value="1.4" lower_limit="1.3" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="843"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="1.0" upper_limit="1.1"/>
                    <measurement group_id="O2" value="1.1" lower_limit="1.1" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="842"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="1.3" upper_limit="1.4"/>
                    <measurement group_id="O2" value="1.4" lower_limit="1.3" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="843"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="1.6" upper_limit="1.7"/>
                    <measurement group_id="O2" value="1.6" lower_limit="1.5" upper_limit="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="842"/>
                    <count group_id="O2" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="1.1" upper_limit="1.2"/>
                    <measurement group_id="O2" value="1.2" lower_limit="1.1" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 22F (Unique to V114)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="843"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="1.7" upper_limit="1.9"/>
                    <measurement group_id="O2" value="8.8" lower_limit="7.4" upper_limit="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 33F (Unique to V114)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="843"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="1.6" upper_limit="1.7"/>
                    <measurement group_id="O2" value="9.9" lower_limit="8.6" upper_limit="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With ≥4-Fold Rise in Serotype-specific OPA Month 6 to Month 7</title>
        <description>Activity for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using a Multiplexed Opsonophagocytic Assay. The percentage of participants who had ≥4-fold rise in OPA titers were calculated from baseline to postvaccination.</description>
        <time_frame>Month 6 (Baseline before Vaccination 2) and Month 7</time_frame>
        <population>The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>V114</title>
            <description>Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
          <group group_id="O2">
            <title>Prevnar 13™</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With ≥4-Fold Rise in Serotype-specific OPA Month 6 to Month 7</title>
          <description>Activity for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using a Multiplexed Opsonophagocytic Assay. The percentage of participants who had ≥4-fold rise in OPA titers were calculated from baseline to postvaccination.</description>
          <population>The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1133"/>
                <count group_id="O2" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="839"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.2" lower_limit="36.8" upper_limit="43.6"/>
                    <measurement group_id="O2" value="21.4" lower_limit="16.8" upper_limit="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="826"/>
                    <count group_id="O2" value="274"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2" lower_limit="16.6" upper_limit="22.1"/>
                    <measurement group_id="O2" value="25.5" lower_limit="20.5" upper_limit="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="837"/>
                    <count group_id="O2" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.8" lower_limit="27.7" upper_limit="34.1"/>
                    <measurement group_id="O2" value="14.9" lower_limit="11.0" upper_limit="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="840"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.5" lower_limit="29.3" upper_limit="35.8"/>
                    <measurement group_id="O2" value="23.0" lower_limit="18.3" upper_limit="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="818"/>
                    <count group_id="O2" value="270"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="2.7" upper_limit="5.5"/>
                    <measurement group_id="O2" value="5.9" lower_limit="3.4" upper_limit="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="842"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" lower_limit="3.3" upper_limit="6.3"/>
                    <measurement group_id="O2" value="6.4" lower_limit="3.9" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="837"/>
                    <count group_id="O2" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" lower_limit="12.3" upper_limit="17.2"/>
                    <measurement group_id="O2" value="7.5" lower_limit="4.7" upper_limit="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="835"/>
                    <count group_id="O2" value="278"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" lower_limit="9.7" upper_limit="14.2"/>
                    <measurement group_id="O2" value="10.4" lower_limit="7.1" upper_limit="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="841"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8" lower_limit="15.3" upper_limit="20.6"/>
                    <measurement group_id="O2" value="8.6" lower_limit="5.6" upper_limit="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="839"/>
                    <count group_id="O2" value="279"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="3.9" upper_limit="7.1"/>
                    <measurement group_id="O2" value="14.3" lower_limit="10.4" upper_limit="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="830"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9" lower_limit="13.5" upper_limit="18.6"/>
                    <measurement group_id="O2" value="12.1" lower_limit="8.5" upper_limit="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="843"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7" lower_limit="15.2" upper_limit="20.4"/>
                    <measurement group_id="O2" value="12.9" lower_limit="9.2" upper_limit="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="837"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" lower_limit="7.3" upper_limit="11.4"/>
                    <measurement group_id="O2" value="11.4" lower_limit="7.9" upper_limit="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 22F (Unique to V114)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="822"/>
                    <count group_id="O2" value="253"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" lower_limit="14.2" upper_limit="19.4"/>
                    <measurement group_id="O2" value="52.6" lower_limit="46.2" upper_limit="58.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 33F (Unique to V114)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="834"/>
                    <count group_id="O2" value="278"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" lower_limit="13.4" upper_limit="18.5"/>
                    <measurement group_id="O2" value="62.6" lower_limit="56.6" upper_limit="68.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With ≥4-Fold Rise in Serotype-specific IgG Month 6 to Month 7</title>
        <description>IgG for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using an electrochemiluminescence assay. The percentage of participants who had ≥ 4-fold rise in IgG concentration are calculated from baseline to postvaccination.</description>
        <time_frame>Month 6 (Baseline before Vaccination 2) and Month 7</time_frame>
        <population>The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>V114</title>
            <description>Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
          <group group_id="O2">
            <title>Prevnar 13™</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With ≥4-Fold Rise in Serotype-specific IgG Month 6 to Month 7</title>
          <description>IgG for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using an electrochemiluminescence assay. The percentage of participants who had ≥ 4-fold rise in IgG concentration are calculated from baseline to postvaccination.</description>
          <population>The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1133"/>
                <count group_id="O2" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="843"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4" lower_limit="13.9" upper_limit="19.0"/>
                    <measurement group_id="O2" value="8.2" lower_limit="5.2" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="842"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" lower_limit="4.8" upper_limit="8.2"/>
                    <measurement group_id="O2" value="13.8" lower_limit="10.0" upper_limit="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="840"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2" lower_limit="12.9" upper_limit="17.8"/>
                    <measurement group_id="O2" value="7.5" lower_limit="4.7" upper_limit="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="843"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" lower_limit="10.0" upper_limit="14.5"/>
                    <measurement group_id="O2" value="5.7" lower_limit="3.3" upper_limit="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="842"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0.2" upper_limit="1.4"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.2" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="843"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="0.3" upper_limit="1.5"/>
                    <measurement group_id="O2" value="2.8" lower_limit="1.2" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="843"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" lower_limit="6.6" upper_limit="10.5"/>
                    <measurement group_id="O2" value="4.3" lower_limit="2.2" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="841"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" lower_limit="4.8" upper_limit="8.2"/>
                    <measurement group_id="O2" value="3.9" lower_limit="2.0" upper_limit="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="843"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" lower_limit="7.9" upper_limit="12.1"/>
                    <measurement group_id="O2" value="3.9" lower_limit="2.0" upper_limit="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="843"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0.2" upper_limit="1.4"/>
                    <measurement group_id="O2" value="0.7" lower_limit="0.1" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="842"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="2.3" upper_limit="4.9"/>
                    <measurement group_id="O2" value="4.3" lower_limit="2.2" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="843"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" lower_limit="6.3" upper_limit="10.1"/>
                    <measurement group_id="O2" value="6.4" lower_limit="3.8" upper_limit="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (Shared)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="842"/>
                    <count group_id="O2" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.1" upper_limit="1.2"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.2" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 22F (Unique to V114)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="843"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" lower_limit="8.2" upper_limit="12.4"/>
                    <measurement group_id="O2" value="64.9" lower_limit="59.0" upper_limit="70.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 33F (Unique to V114)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="843"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" lower_limit="5.8" upper_limit="9.5"/>
                    <measurement group_id="O2" value="75.9" lower_limit="70.5" upper_limit="80.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Non-serious adverse events: Up to 14 days after each vaccination; Serious adverse events and all-cause mortality: Up to Month 7 (Up to 44 days after vaccination 2).</time_frame>
      <desc>The analysis population included all randomized participants who received the relevant study vaccination for the timepoint of interest and were included in the intervention group according to the intervention they received. One participant in the Prevnar 13™ group incorrectly received V114 and was included in the V114 group for safety analyses.</desc>
      <group_list>
        <group group_id="E1">
          <title>V114</title>
          <description>Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
        </group>
        <group group_id="E2">
          <title>Prevnar 13™</title>
          <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
        </group>
        <group group_id="E3">
          <title>V114 (Post-PNEUMOVAX™23)</title>
          <description>Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
        </group>
        <group group_id="E4">
          <title>Prevnar 13™ (Post-PNEUMOVAX™23)</title>
          <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1134"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="1134"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="378"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1036"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pulseless electrical activity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes insipidus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Obstructive pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Haematoma infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Peritonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Eyelid injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Gastrointestinal neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>IIIrd nerve paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Drug dependence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Physical assault</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive urgency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="934" subjects_at_risk="1134"/>
                <counts group_id="E2" subjects_affected="298" subjects_at_risk="378"/>
                <counts group_id="E3" subjects_affected="771" subjects_at_risk="1036"/>
                <counts group_id="E4" subjects_affected="258" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="510" subjects_affected="389" subjects_at_risk="1134"/>
                <counts group_id="E2" events="186" subjects_affected="139" subjects_at_risk="378"/>
                <counts group_id="E3" events="366" subjects_affected="312" subjects_at_risk="1036"/>
                <counts group_id="E4" events="139" subjects_affected="106" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="180" subjects_affected="174" subjects_at_risk="1134"/>
                <counts group_id="E2" events="57" subjects_affected="56" subjects_at_risk="378"/>
                <counts group_id="E3" events="237" subjects_affected="235" subjects_at_risk="1036"/>
                <counts group_id="E4" events="91" subjects_affected="88" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="931" subjects_affected="865" subjects_at_risk="1134"/>
                <counts group_id="E2" events="292" subjects_affected="260" subjects_at_risk="378"/>
                <counts group_id="E3" events="762" subjects_affected="714" subjects_at_risk="1036"/>
                <counts group_id="E4" events="252" subjects_affected="231" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="257" subjects_affected="251" subjects_at_risk="1134"/>
                <counts group_id="E2" events="84" subjects_affected="84" subjects_at_risk="378"/>
                <counts group_id="E3" events="307" subjects_affected="305" subjects_at_risk="1036"/>
                <counts group_id="E4" events="113" subjects_affected="113" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="180" subjects_affected="144" subjects_at_risk="1134"/>
                <counts group_id="E2" events="63" subjects_affected="44" subjects_at_risk="378"/>
                <counts group_id="E3" events="130" subjects_affected="124" subjects_at_risk="1036"/>
                <counts group_id="E4" events="47" subjects_affected="38" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="377" subjects_affected="327" subjects_at_risk="1134"/>
                <counts group_id="E2" events="113" subjects_affected="100" subjects_at_risk="378"/>
                <counts group_id="E3" events="260" subjects_affected="250" subjects_at_risk="1036"/>
                <counts group_id="E4" events="99" subjects_affected="88" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="425" subjects_affected="300" subjects_at_risk="1134"/>
                <counts group_id="E2" events="122" subjects_affected="94" subjects_at_risk="378"/>
                <counts group_id="E3" events="274" subjects_affected="220" subjects_at_risk="1036"/>
                <counts group_id="E4" events="93" subjects_affected="73" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments. Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

